CTOs on the Move

ProLung Incorporated

www.prolunginc.com

 
ProLung`s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.prolunginc.com
  • 757 E. South Temple Suite 150
    Salt Lake City, UT USA 84102
  • Phone: 801.736.0729

Executives

Name Title Contact Details

Similar Companies

Irvine Pharmaceutical Services,

Irvine Pharmaceutical Services, is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mason Dental Lab

Mason Dental Lab is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BTE Technologies

BTE Technologies is a Hanover, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VetConnect

VetConnect is a Westbrook, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Natera

Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.